The U.S. Court of Federal Claims held that pharmaceutical patent litigation expenses under the Hatch-Waxman Act were deductible business expenses under Sec. 162. The court arrived at this conclusion ...
The Generic Drug User Fee Amendments, designed to facilitate the delivery of safe and effective generic drugs to the public and improve the predictability of the ANDA assessment process, has undergone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback